Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

The deubiquitinase CYLD targets Smad7 protein to regulate transforming growth factor β (TGF-β) signaling and the development of regulatory T cells.

Zhao Y, Thornton AM, Kinney MC, Ma CA, Spinner JJ, Fuss IJ, Shevach EM, Jain A.

J Biol Chem. 2011 Nov 25;286(47):40520-30. doi: 10.1074/jbc.M111.292961. Epub 2011 Sep 19.

2.
3.

Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression.

Fantini MC, Rizzo A, Fina D, Caruso R, Sarra M, Stolfi C, Becker C, Macdonald TT, Pallone F, Neurath MF, Monteleone G.

Gastroenterology. 2009 Apr;136(4):1308-16, e1-3. doi: 10.1053/j.gastro.2008.12.053. Epub 2008 Dec 27.

PMID:
19192480
4.

Defective response of CD4(+) T cells to retinoic acid and TGFβ in systemic lupus erythematosus.

Sobel ES, Brusko TM, Butfiloski EJ, Hou W, Li S, Cuda CM, Abid AN, Reeves WH, Morel L.

Arthritis Res Ther. 2011 Jun 27;13(3):R106. doi: 10.1186/ar3387.

5.

MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu.

Hossain DM, Panda AK, Chakrabarty S, Bhattacharjee P, Kajal K, Mohanty S, Sarkar I, Sarkar DK, Kar SK, Sa G.

Immunology. 2015 Apr;144(4):561-73. doi: 10.1111/imm.12397.

6.

HSP70 enhances immunosuppressive function of CD4(+)CD25(+)FoxP3(+) T regulatory cells and cytotoxicity in CD4(+)CD25(-) T cells.

Wachstein J, Tischer S, Figueiredo C, Limbourg A, Falk C, Immenschuh S, Blasczyk R, Eiz-Vesper B.

PLoS One. 2012;7(12):e51747. doi: 10.1371/journal.pone.0051747. Epub 2012 Dec 26.

7.

Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses.

Reiley WW, Jin W, Lee AJ, Wright A, Wu X, Tewalt EF, Leonard TO, Norbury CC, Fitzpatrick L, Zhang M, Sun SC.

J Exp Med. 2007 Jun 11;204(6):1475-85. Epub 2007 Jun 4.

8.

The tumor suppressor CYLD controls the function of murine regulatory T cells.

Reissig S, Hövelmeyer N, Weigmann B, Nikolaev A, Kalt B, Wunderlich TF, Hahn M, Neurath MF, Waisman A.

J Immunol. 2012 Nov 15;189(10):4770-6. doi: 10.4049/jimmunol.1201993. Epub 2012 Oct 12.

9.

Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction.

Kim YC, Kim KK, Shevach EM.

Immunology. 2010 Aug;130(4):484-93. doi: 10.1111/j.1365-2567.2010.03269.x. Epub 2010 Apr 12.

10.

Aurintricarboxylic acid promotes the conversion of naive CD4+CD25- T cells into Foxp3-expressing regulatory T cells.

Lim DG, Park YH, Kim SE, Kim YH, Park CS, Kim SC, Park CG, Han DJ.

Int Immunol. 2011 Sep;23(9):583-92. doi: 10.1093/intimm/dxr058. Epub 2011 Jul 12.

11.

Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7.

Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF.

J Immunol. 2004 May 1;172(9):5149-53.

12.

CARMA1 regulation of regulatory T cell development involves modulation of interleukin-2 receptor signaling.

Lee AJ, Wu X, Cheng H, Zhou X, Cheng X, Sun SC.

J Biol Chem. 2010 May 21;285(21):15696-703. doi: 10.1074/jbc.M109.095190. Epub 2010 Mar 16.

13.

All-trans retinoic acid promotes TGF-β-induced Tregs via histone modification but not DNA demethylation on Foxp3 gene locus.

Lu L, Ma J, Li Z, Lan Q, Chen M, Liu Y, Xia Z, Wang J, Han Y, Shi W, Quesniaux V, Ryffel B, Brand D, Li B, Liu Z, Zheng SG.

PLoS One. 2011;6(9):e24590. doi: 10.1371/journal.pone.0024590. Epub 2011 Sep 13.

14.

PKCθ/β and CYLD are antagonistic partners in the NFκB and NFAT transactivation pathways in primary mouse CD3+ T lymphocytes.

Thuille N, Wachowicz K, Hermann-Kleiter N, Kaminski S, Fresser F, Lutz-Nicoladoni C, Leitges M, Thome M, Massoumi R, Baier G.

PLoS One. 2013;8(1):e53709. doi: 10.1371/journal.pone.0053709. Epub 2013 Jan 15.

15.

Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.

Arsura M, Panta GR, Bilyeu JD, Cavin LG, Sovak MA, Oliver AA, Factor V, Heuchel R, Mercurio F, Thorgeirsson SS, Sonenshein GE.

Oncogene. 2003 Jan 23;22(3):412-25.

PMID:
12545162
16.

A dynamic dual role of IL-2 signaling in the two-step differentiation process of adaptive regulatory T cells.

Guo Z, Khattar M, Schroder PM, Miyahara Y, Wang G, He X, Chen W, Stepkowski SM.

J Immunol. 2013 Apr 1;190(7):3153-62. doi: 10.4049/jimmunol.1200751. Epub 2013 Feb 20.

17.

Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells.

Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J, Monteleone G, Rose-John S, Neurath MF, Becker C.

J Immunol. 2007 Aug 15;179(4):2041-5.

18.

Integrated T-cell receptor and costimulatory signals determine TGF-β-dependent differentiation and maintenance of Foxp3+ regulatory T cells.

Gabryšová L, Christensen JR, Wu X, Kissenpfennig A, Malissen B, O'Garra A.

Eur J Immunol. 2011 May;41(5):1242-8. doi: 10.1002/eji.201041073. Epub 2011 Apr 11.

19.

Serum response factor controls CYLD expression via MAPK signaling pathway.

Liang G, Ahlqvist K, Pannem R, Posern G, Massoumi R.

PLoS One. 2011 May 5;6(5):e19613. doi: 10.1371/journal.pone.0019613.

20.

Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells.

Huber S, Stahl FR, Schrader J, Lüth S, Presser K, Carambia A, Flavell RA, Werner S, Blessing M, Herkel J, Schramm C.

J Immunol. 2009 Apr 15;182(8):4633-40. doi: 10.4049/jimmunol.0803143.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk